vs
AerSale Corp（ASLE）与Beam Therapeutics Inc.（BEAM）财务数据对比。点击上方公司名可切换其他公司
Beam Therapeutics Inc.的季度营收约是AerSale Corp的1.3倍（$114.1M vs $90.9M），Beam Therapeutics Inc.净利率更高（214.1% vs 5.9%，领先208.2%），Beam Therapeutics Inc.同比增速更快（279.5% vs -4.0%），AerSale Corp自由现金流更多（$9.8M vs $-87.0M）
AerSale Corp总部位于美国佛罗里达州多拉市，是一家面向航空领域的全球供应商，主要为客运及货运航空公司、政府机构、跨国整机制造商与独立维修机构提供商用喷气飞机二手整机、发动机、航空耗材，并提供航空工程服务，同时该公司也是飞机机队回收协会的成员企业。
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
ASLE vs BEAM — 直观对比
营收规模更大
BEAM
是对方的1.3倍
$90.9M
营收增速更快
BEAM
高出283.5%
-4.0%
净利率更高
BEAM
高出208.2%
5.9%
自由现金流更多
ASLE
多$96.8M
$-87.0M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $90.9M | $114.1M |
| 净利润 | $5.4M | $244.3M |
| 毛利率 | 34.1% | — |
| 营业利润率 | 7.8% | -15.3% |
| 净利率 | 5.9% | 214.1% |
| 营收同比 | -4.0% | 279.5% |
| 净利润同比 | 99.7% | 370.4% |
| 每股收益（稀释后） | $0.10 | $2.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASLEBEAM
| Q4 25 | $90.9M | $114.1M | ||
| Q3 25 | $71.2M | — | ||
| Q2 25 | $107.4M | — | ||
| Q1 25 | $65.8M | — | ||
| Q4 24 | $94.7M | — | ||
| Q3 24 | $82.7M | — | ||
| Q2 24 | $77.1M | — | ||
| Q1 24 | $90.5M | — |
净利润ASLEBEAM
| Q4 25 | $5.4M | $244.3M | ||
| Q3 25 | $-120.0K | — | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $-5.3M | — | ||
| Q4 24 | $2.7M | — | ||
| Q3 24 | $509.0K | — | ||
| Q2 24 | $-3.6M | — | ||
| Q1 24 | $6.3M | — |
毛利率ASLEBEAM
| Q4 25 | 34.1% | — | ||
| Q3 25 | 30.2% | — | ||
| Q2 25 | 32.9% | — | ||
| Q1 25 | 27.3% | — | ||
| Q4 24 | 31.4% | — | ||
| Q3 24 | 28.6% | — | ||
| Q2 24 | 28.2% | — | ||
| Q1 24 | 31.8% | — |
营业利润率ASLEBEAM
| Q4 25 | 7.8% | -15.3% | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 11.7% | — | ||
| Q1 25 | -10.1% | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | -2.4% | — | ||
| Q1 24 | 5.2% | — |
净利率ASLEBEAM
| Q4 25 | 5.9% | 214.1% | ||
| Q3 25 | -0.2% | — | ||
| Q2 25 | 8.0% | — | ||
| Q1 25 | -8.0% | — | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | -4.7% | — | ||
| Q1 24 | 6.9% | — |
每股收益（稀释后）ASLEBEAM
| Q4 25 | $0.10 | $2.53 | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $0.18 | — | ||
| Q1 25 | $-0.10 | — | ||
| Q4 24 | $0.05 | — | ||
| Q3 24 | $0.01 | — | ||
| Q2 24 | $-0.07 | — | ||
| Q1 24 | $0.12 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.4M | $1.2B |
| 总债务越低越好 | $1.3M | — |
| 股东权益账面价值 | $424.4M | $1.2B |
| 总资产 | $640.5M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资ASLEBEAM
| Q4 25 | $4.4M | $1.2B | ||
| Q3 25 | $5.3M | — | ||
| Q2 25 | $5.7M | — | ||
| Q1 25 | $4.7M | — | ||
| Q4 24 | $4.7M | — | ||
| Q3 24 | $9.8M | — | ||
| Q2 24 | $4.3M | — | ||
| Q1 24 | $2.6M | — |
总债务ASLEBEAM
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $907.0K | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $376.0K | — | ||
| Q2 24 | $522.0K | — | ||
| Q1 24 | $3.5M | — |
股东权益ASLEBEAM
| Q4 25 | $424.4M | $1.2B | ||
| Q3 25 | $417.1M | — | ||
| Q2 25 | $415.9M | — | ||
| Q1 25 | $406.5M | — | ||
| Q4 24 | $455.6M | — | ||
| Q3 24 | $451.5M | — | ||
| Q2 24 | $449.8M | — | ||
| Q1 24 | $452.0M | — |
总资产ASLEBEAM
| Q4 25 | $640.5M | $1.5B | ||
| Q3 25 | $646.3M | — | ||
| Q2 25 | $646.7M | — | ||
| Q1 25 | $646.1M | — | ||
| Q4 24 | $604.7M | — | ||
| Q3 24 | $601.5M | — | ||
| Q2 24 | $598.7M | — | ||
| Q1 24 | $571.7M | — |
负债/权益比ASLEBEAM
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.4M | $-83.3M |
| 自由现金流经营现金流 - 资本支出 | $9.8M | $-87.0M |
| 自由现金流率自由现金流/营收 | 10.8% | -76.3% |
| 资本支出强度资本支出/营收 | 1.7% | 3.3% |
| 现金转化率经营现金流/净利润 | 2.11× | -0.34× |
| 过去12个月自由现金流最近4个季度 | $-29.1M | — |
8季度趋势，按日历期对齐
经营现金流ASLEBEAM
| Q4 25 | $11.4M | $-83.3M | ||
| Q3 25 | $-8.9M | — | ||
| Q2 25 | $19.8M | — | ||
| Q1 25 | $-45.2M | — | ||
| Q4 24 | $37.5M | — | ||
| Q3 24 | $10.4M | — | ||
| Q2 24 | $-15.3M | — | ||
| Q1 24 | $-21.5M | — |
自由现金流ASLEBEAM
| Q4 25 | $9.8M | $-87.0M | ||
| Q3 25 | $-9.8M | — | ||
| Q2 25 | $18.6M | — | ||
| Q1 25 | $-47.6M | — | ||
| Q4 24 | $32.3M | — | ||
| Q3 24 | $8.9M | — | ||
| Q2 24 | $-18.9M | — | ||
| Q1 24 | $-25.0M | — |
自由现金流率ASLEBEAM
| Q4 25 | 10.8% | -76.3% | ||
| Q3 25 | -13.8% | — | ||
| Q2 25 | 17.3% | — | ||
| Q1 25 | -72.4% | — | ||
| Q4 24 | 34.0% | — | ||
| Q3 24 | 10.7% | — | ||
| Q2 24 | -24.6% | — | ||
| Q1 24 | -27.7% | — |
资本支出强度ASLEBEAM
| Q4 25 | 1.7% | 3.3% | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 3.7% | — | ||
| Q4 24 | 5.6% | — | ||
| Q3 24 | 1.9% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 3.9% | — |
现金转化率ASLEBEAM
| Q4 25 | 2.11× | -0.34× | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.31× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 13.89× | — | ||
| Q3 24 | 20.52× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -3.42× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASLE
| Products | $57.8M | 64% |
| Maintenance | $23.2M | 26% |
| Leasing Arrangements | $9.9M | 11% |
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
